Companies /Healthcare
AMGEN Inc
NASDAQ: AMGN Drug Manufacturers - General
$468.11
▲ $2.88 (+0.62%) today
Markets closed · 11:59pm ET

Amgen (AMGN) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
100%
EPS beat rate
+23.41%
Avg. EPS surprise
Consecutive EPS beats
AMGN vs Market · 30-day return after each reportAMGNS&P 500
0%+3%+6%+2.1%+5.2%Q1 25−1.6%+2.5%Q2 25+0.4%+0.9%Q3 25+2.9%−1.2%Q4 25+2.6%+4.7%Q1 26+7.2%+0.1%Q2 26
0%+3%+6%Q1 25Q3 25Q1 26
AMGN EPS Trend · estimate vs actualEstimateActual
$0$2$4$6$4.26$4.90Q1 25$3.12$6.02Q2 25$5.01$5.64Q3 25$4.73$5.29Q4 25$4.77$5.15Q1 26$5.62$6.29Q2 26$5.78$6.45Q3 26
$0$2$4$6Q1 25Q3 25Q1 26Q3 26
AMGN Revenue Trend · estimate vs actualEstimateActual
$0$3.0B$6.0B$9.0B$8.0B$8.1BQ1 25$8.9B$9.2BQ2 25$9.0B$9.6BQ3 25$9.5B$9.9BQ4 25$8.6B$8.6BQ1 26$9.4B$10.1BQ2 26$10.1B$10.4BQ3 26
$0$3.0B$6.0B$9.0BQ1 25Q3 25Q1 26Q3 26

How Often Does Amgen Beat Earnings Estimates?

Amgen beat EPS estimates in 7 of its last 7 reported quarters, and has beaten 7 quarters in a row.

AMGN quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 GAAP diluted EPS of $7.08 includes net gains from equity investments, noncash amortization of acquired intangible assets and other items, all excluded from non-GAAP EPS of $6.45. The prior-year quarter included Otezla intangible asset impairment charges. $6.45 est. $5.78 +11.55% $10.4B est. $10.1B +2.95%
Q2 2026 $6.29 est. $5.62 +11.97% $10.1B est. $9.4B +6.73%
Q1 2026 $5.15 est. $4.77 +7.97% $8.6B est. $8.6B +0.55%
Q4 2025 $5.29 est. $4.73 +11.84% $9.9B est. $9.5B +4.25%
Q3 2025 $5.64 est. $5.01 +12.57% $9.6B est. $9.0B +6.59%
Q2 2025 $6.02 est. $3.12 +92.95% $9.2B est. $8.9B +3.01%
Q1 2025 $4.90 est. $4.26 +15.02% $8.1B est. $8.0B +1.42%

Figures from SEC filings and company reports. Not investment advice.